BioSpace News Archive

Novel approach successfully treated experimental model of rare genetic condition

Guardant Health, Inc. announced the company will be participating in two upcoming investor conferences.

Revolution Medicines, Inc. announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.

Lexington Biosciences, Inc. has allowed the license with the Lawrence Berkeley National Laboratories, which was being used in the HeartSentry technology, to terminate due to non-payment of its minimum annual royalty fees which were due in August 2018 and August 2019..

Creative Science Properties, Inc. announced today that it will change its name to IQHQ, Inc. IQHQ also announced that it has successfully completed a $770 million equity raise, including a private placement financing to qualified institutional buyers under Rule 144A of the Securities Act of 1933 and project specific equity investments.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019.

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite, President and Chief Executive Officer, will present updates on Fluidigm’s business at the following investor conferences in March:

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2019 after market close on Monday, February 24, 2020.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs post-market on February 19, 2020.

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identify a new CEO following the recent passing of Joseph Darling